API | crenolanib

crenolanib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Crenolanib besylate is an investigational inhibitor being developed by AROG Pharmaceuticals, LLC. The compound is currently being evaluated for safety and efficacy in clinical trials for various types of cancer, including acute myeloid leukemia (AML), gastrointestinal stromal tumor (GIST), and glioma. Crenolanib is an orally bioavailable benzimidazole that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTK) FLT3, PDGFR α, and PDGFR β. Unlike most RTK inhibitors, crenolanib is a type I mutant-specific inhibitor that preferentially binds to phosphorylated active kinases with the ‘DFG in’ conformation motif. ^Wikipedia

Chemistry

SMILES: CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
InChIKey: DYNHJHQFHQTFTP-UHFFFAOYSA-N
Mol. Mass: 443.55
ALogP: 3.92 Partition coefficient
ChEMBL Molecule:
crenolanib

More Chemistry

Pharmacology

Mechanisms of Action:
- Platelet-derived growth factor receptor alpha (Homo sapiens) ^UniProt
- Platelet-derived growth factor receptor beta (Homo sapiens) ^UniProt
- Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

aro-002 | cp-868596 | cp-868,596 | crenolanib

Organizations (12)

Research & Development (12)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Diffuse Intrinsic Pontine Glioma (Phase 1)

Esophageal Neoplasms (Phase 1)

Gastrointestinal Stromal Tumors (Phase 3)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Leukemia, Myeloid, Acute (Phase 3)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 14
# of Trial Organizations: 12

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue